News and Announcements
Eli Lilly to buy Kelonia Therapeutics for up to $7bn
By Michele Maatouk
Date: Monday 20 Apr 2026
(Sharecast News) - Eli Lilly said on Monday that it has agreed to buy Boston-based Kelonia Therapeutics, a clinical-stage biotechnology company pioneering in vivo gene delivery, for up to $7bn in cash.
Under the terms of the agreement, Lilly will make an upfront payment of $3.25bn, and subsequent payments upon achievement of certain clinical, regulatory and commercial milestones. The deal is expected to close in the second half of this year.
Kelonia has developed a proprietary in vivo gene placement system (iGPS ) that uses specially engineered lentiviral-based particles designed to efficiently and selectively enter T-cells inside the body, allowing the patient's own body to generate chimeric antigen receptor T-cell (CAR-T) therapies that can treat underlying disease.
The company's lead program, KLN-1010, is an investigational, one-time intravenous gene therapy that generates anti-B-cell maturation antigen (BCMA) CAR-T cells, targeting the BCMA protein expressed on the surface of multiple myeloma cells.
Lilly said KLN-1010 could represent a transformative advance in the treatment of multiple myeloma by eliminating the complexities of ex vivo patient-specific cell therapy manufacturing, and pre-administration chemotherapy.
Jacob Van Naarden, executive vice president and president of Lilly Oncology and head of corporate business development, said: "Autologous CAR-T therapies have meaningfully improved outcomes for patients with various cancers, but significant manufacturing, safety, and access barriers mean that only a fraction of eligible patients actually receive them. Kelonia's in vivo platform has the potential to change that by delivering rapid, durable responses in a far simpler, off-the-shelf format.
"The early clinical data for KLN-1010 are highly encouraging, both as a potential step forward for patients with multiple myeloma and as proof of concept for Kelonia's platform. We look forward to working together with the Kelonia team to rapidly advance KLN-1010 to address patient need and recognise the full potential of their platform in other conditions where patients may benefit."
Article Archive
Free Membership To Digital Look
Discover the full range of Investor's Tools and Services from Digital Look - voted 'Best Research & Information Provider 2007' by Investors Chronicle.
En HeaderFooterDLYou are here: research